| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Business Officer
1 company
Hicks Derek is an EVP, Chief Business Officer at NTLA. Recent filings cover 0 purchases and 3 sales. Those positions are worth an estimated $720K at current prices.
Our model assigns Hicks Derek a strong insider score of 71/100, based on 3 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +35.7%.
Hicks Derek's largest disclosed position is in NTLA as EVP, Chief Business Officer, worth about $720K. The recent filings there lean toward selling, a net 12,191 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 3, 2025 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Business Officer | Sell | 6,502 | $12.18 | $79,194.36 | -9.8% | -43.2% | -24.1% | |
| Jan 3, 2024 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Business Officer | Sell | 3,877 | $29.46 | $114,216.42 | -9.5% | -14.9% | -58.6% | |
| Jan 4, 2023 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Business Officer | Sell | 1,812 | $37.21 | $67,424.52 | -9.5% | -7.5% | -24.6% |